|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Litzenburger BC, Creighton CJ, Tsimelzon
A, et al: High IGF-IR activity in triple-negative breast cancer
cell lines and tumorgrafts correlates with sensitivity to
anti-IGF-IR therapy. Clin Cancer Res. 17:2314–2327. 2011.
View Article : Google Scholar :
|
|
3
|
Rakha EA, Reis-Filho JS and Ellis IO:
Basal-like breast cancer: a critical review. J Clin Oncol.
26:2568–2581. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liedtke C, Mazouni C, Hess KR, Andre F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brouckaert O, Wildiers H, Floris G and
Neven P: Update on triple-negative breast cancer: prognosis and
management strategies. Int J Womens Health. 4:511–520.
2012.PubMed/NCBI
|
|
7
|
Cao H, Yan M, Wang S, Zheng T, Xu R, Chen
Y and Liu Y: Clinical characteristics and prognosis of
triple-negative breast cancer. Chin-Ger J Clin Oncol. 8:471–475.
2009. View Article : Google Scholar
|
|
8
|
Oakman C, Moretti E, Galardi F, Biagioni
C, Santarpia L, Biganzoli L and Di Leo A: Adjuvant systemic
treatment for individual patients with triple negative breast
cancer. Breast. 20(Suppl 3): S135–S141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kashiwagi S, Yashiro M, Takashima T,
Nomura S, Noda S, Kawajiri H, Ishikawa T, Wakasa K and Hirakawa K:
Significance of E-cadherin expression in triple-negative breast
cancer. Br J Cancer. 103:249–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dumont N, Bakin AV and Arteaga CL:
Autocrine transforming growth factor-beta signaling mediates
Smad-independent motility in human cancer cells. J Biol Chem.
278:3275–3285. 2003. View Article : Google Scholar
|
|
11
|
Tan AR, Alexe G and Reiss M: Transforming
growth factor-beta signaling: emerging stem cell target in
metastatic breast cancer? Breast Cancer Res Treat. 115:453–495.
2009. View Article : Google Scholar :
|
|
12
|
Adams J, Carder PJ, Downey S, Forbes MA,
MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ,
et al: Vascular endothelial growth factor (VEGF) in breast cancer:
comparison of plasma, serum, and tissue VEGF and microvessel
density and effects of tamoxifen. Cancer Res. 60:2898–2905.
2000.PubMed/NCBI
|
|
13
|
George ML, Eccles SA, Tutton MG, Abulafi
AM and Swift RI: Correlation of plasma and serum vascular
endothelial growth factor levels with platelet count in colorectal
cancer: clinical evidence of platelet scavenging? Clin Cancer Res.
6:3147–3152. 2000.PubMed/NCBI
|
|
14
|
Pollak MN, Schernhammer ES and Hankinson
SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer.
4:505–518. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hankinson SE: Circulating levels of sex
steroids and prolactin in premenopausal women and risk of breast
cancer. Adv Exp Med Biol. 617:161–169. 2008.PubMed/NCBI
|
|
16
|
Reiss K, Wang JY, Romano G, Furnari FB,
Cavenee WK, Morrione A, Tu X and Baserga R: IGF-I receptor
signaling in a prostatic cancer cell line with a PTEN mutation.
Oncogene. 19:2687–2694. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Valentinis B, Navarro M, Zanocco-Marani T,
Edmonds P, McCormick J, Morrione A, Sacchi A, Romano G, Reiss K and
Baserga R: Insulin receptor substrate-1, p70S6K, and cell size in
transformation and differentiation of hemopoietic cells. J Biol
Chem. 275:25451–25459. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guerra FK, Eijan AM, Puricelli L, Alonso
DF, Bal de Kier Joffé E, Kornblihgtt AR, Charreau EH and Elizalde
PV: Varying patterns of expression of insulin-like growth factors I
and II and their receptors in murine mammary adenocarcinomas of
different metastasizing ability. Int J Cancer. 65:812–820. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iva nović V, To dorović-Ra ković N, D
emajo M, Nesković-Konstantinović Z, Subota V,
Ivanisević-Milovanović O and Nikolić-Vukosavljević D: Elevated
plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in
patients with advanced breast cancer: association with disease
progression. Eur J Cancer. 39:454–461. 2003. View Article : Google Scholar
|
|
22
|
Jones C, Nonni AV, Fulford L, Merrett S,
Chaggar R, Eusebi V and Lakhani SR: CGH analysis of ductal
carcinoma of the breast with basaloid/myoepithelial cell
differentiation. Br J Cancer. 85:422–427. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Chao L, Ma G, Chen L, Tian B, Zang
Y and Sun J: Increased expression of osteopontin in patients with
triple-negative breast cancer. Eur J Clin Invest. 38:438–446. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sheen-Chen SM, Chen HS, Sheen CW, Eng HL
and Chen WJ: Serum levels of transforming growth factor beta1 in
patients with breast cancer. Arch Surg. 136:937–940. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Massagué J, Cheifetz S, Laiho M, Ralph DA,
Weis FM and Zentella A: Transforming growth factor-beta. Cancer
Surv. 12:81–103. 1992.PubMed/NCBI
|
|
27
|
Reiss M: TGF-beta and cancer. Microbes
Infect. 1:1327–1347. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shipitsin M, Campbell LL, Argani P,
Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T,
Serebryiskaya T, Beroukhim R, Hu M, et al: Molecular definition of
breast tumor heterogeneity. Cancer Cell. 11:259–273. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Buck M, von der Fecht J and Knabbe C:
Antiestrogenic regulation of transforming growth factor beta
receptors I and II in human breast cancer cells. Ann NY Acad Sci.
963:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kang Y, He W, Tulley S, Gupta GP,
Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL and
Massagué J: Breast cancer bone metastasis mediated by the Smad
tumor suppressor pathway. Proc Natl Acad Sci USA. 102:13909–13914.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin JJ, Selander K, Chirgwin JM, Dallas M,
Grubbs BG, Wieser R, Massagué J, Mundy GR and Guise TA: TGF-beta
signaling blockade inhibits PTHrP secretion by breast cancer cells
and bone metastases development. J Clin Invest. 103:197–206. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang B, Vu M, Booker T, Santner SJ, Miller
FR, Anver MR and Wakefield LM: TGF-beta switches from tumor
suppressor to prometastatic factor in a model of breast cancer
progression. J Clin Invest. 112:1116–1124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kingsley LA, Fournier PG, Chirgwin JM and
Guise TA: Molecular biology of bone metastasis. Mol Cancer Ther.
6:2609–2617. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kareddula A, Zachariah E, Notterman D and
Reiss M: Transforming growth factor-b signaling strength determines
target gene expression profile in human keratinocytes. J Epithel
Biol Pharmaco. 1:40–94. 2008. View Article : Google Scholar
|
|
35
|
Marrogi AJ, Munshi A, Merogi AJ, Ohadike
Y, El-Habashi A, Marrogi OL and Freeman SM: Study of tumor
infiltrating lymphocytes and transforming growth factor-beta as
prognostic factors in breast carcinoma. Int J Cancer. 74:492–501.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gorsch SM, Memoli VA, Stukel TA, Gold LI
and Arrick BA: Immunohistochemical staining for transforming growth
factor beta 1 associates with disease progression in human breast
cancer. Cancer Res. 52:6949–6952. 1992.PubMed/NCBI
|
|
37
|
Desruisseau S, Palmari J, Giusti C, Romain
S, Martin PM and Berthois Y: Determination of TGFbeta1 protein
level in human primary breast cancers and its relationship with
survival. Br J Cancer. 94:239–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dave H, Shah M, Trivedi S and Shukla S:
Prognostic utility of circulating transforming growth factor beta 1
in breast cancer patients. Int J Biol Markers. 27:53–59. 2012.
View Article : Google Scholar
|
|
39
|
Taha FM, Zeeneldin AA, Helal AM, Gaber AA,
Sallam YA, Ramadan H and Moneer MM: Prognostic value of serum
vascular endothelial growth factor in Egyptian females with
metastatic triple negative breast cancer. Clin Biochem.
42:1420–1426. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Berns EM, Klijn JG, Look MP, et al:
Combined vascular endo-thelial growth factor and TP53 status
predicts poor response to tamoxifen therapy in estrogen
receptor-positive advanced breast cancer. Clin Cancer Res.
9:1253–1258. 2003.PubMed/NCBI
|
|
41
|
Foekens JA, Peters HA, Grebenchtchikov N,
Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH,
Sweep CG and Klijn JG: High tumor levels of vascular endo-thelial
growth factor predict poor response to systemic therapy in advanced
breast cancer. Cancer Res. 61:5407–5414. 2001.PubMed/NCBI
|
|
42
|
Greenberg S and Rugo HS: Triple-negative
breast cancer: role of antiangiogenic agents. Cancer J. 16:33–38.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Björndahl M, Cao R, Nissen LJ, et al:
Insulin-like growth factors 1 and 2 induce lymphangiogenesis in
vivo. Proc Natl Acad Sci USA. 102:15593–15598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Moschos SJ and Mantzoros CS: The role of
the IGF system in cancer: from basic to clinical studies and
clinical applications. Oncology. 63:317–332. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rubin R and Baserga R: Insulin-like growth
factor-I receptor. Its role in cell proliferation, apoptosis, and
tumorigenicity. Lab Invest. 73:311–331. 1995.PubMed/NCBI
|
|
46
|
Dunn SE, Kari FW, French J, Leininger JR,
Travlos G, Wilson R and Barrett JC: Dietary restriction reduces
insulin-like growth factor I levels, which modulates apoptosis,
cell proliferation, and tumor progression in p53-deficient mice.
Cancer Res. 57:4667–4672. 1997.PubMed/NCBI
|
|
47
|
Gooch JL, Van Den Berg CL and Yee D:
Insulin-like growth factor (IGF)-I rescues breast cancer cells from
chemotherapy-induced cell death - proliferative and anti-apoptotic
effects. Breast Cancer Res Treat. 56:1–10. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Decensi A, Veronesi U, Miceli R, Johansson
H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa
A, et al: Relationships between plasma insulin-like growth factor-I
and insulin-like growth factor binding protein-3 and second breast
cancer risk in a prevention trial of fenretinide. Clin Cancer Res.
9:4722–4729. 2003.PubMed/NCBI
|
|
49
|
Gail MH, Costantino JP, Bryant J, Croyle
R, Freedman L, Helzlsouer K and Vogel V: Weighing the risks and
benefits of tamoxifen treatment for preventing breast cancer. J
Natl Cancer Inst. 91:1829–1846. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yarden RI, Wilson MA and Chrysogelos SA:
Estrogen suppression of EGFR expression in breast cancer cells: a
possible mechanism to modulate growth. J Cell Biochem. 81(Suppl
36): 232–246. 2001. View Article : Google Scholar
|
|
51
|
Haffner MC, Petridou B, Peyrat JP,
Révillion F, Müller-Holzner E, Daxenbichler G, Marth C and Doppler
W: Favorable prognostic value of SOCS2 and IGF-I in breast cancer.
BMC Cancer. 7:1362007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shin A, Ren Z, Shu XO, Cai Q, Gao YT and
Zheng W: Expression patterns of insulin-like growth factor 1
(IGF-I) and its receptor in mammary tissues and their associations
with breast cancer survival. Breast Cancer Res Treat. 105:55–61.
2007. View Article : Google Scholar
|
|
53
|
Minami CA, Chung DU and Chang HR:
Management options in triple-negative breast cancer. Breast Cancer
(Auckl). 5:175–199. 2011.
|
|
54
|
Sarfstein R, Maor S, Reizner N,
Abramovitch S and Werner H: Transcriptional regulation of the
insulin-like growth factor-I receptor gene in breast cancer. Mol
Cell Endocrinol. 252:241–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Valentinis B, Romano G, Peruzzi F,
Morrione A, Prisco M, Soddu S, Cristofanelli B, Sacchi A and
Baserga R: Growth and differentiation signals by the insulin-like
growth factor 1 receptor in hemopoietic cells are mediated through
different pathways. J Biol Chem. 274:12423–12430. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Munagala R, Aqil F and Gupta RC: Promising
molecular targeted therapies in breast cancer. Indian J Pharmacol.
43:236–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shimizu C, Hasegawa T, Tani Y, Takahashi
F, Takeuchi M, Watanabe T, Ando M, Katsumata N and Fujiwara Y:
Expression of insulin-like growth factor 1 receptor in primary
breast cancer: immunohistochemical analysis. Hum Pathol.
35:1537–1542. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pizon M, Zimon DS, Pachmann U and Pachmann
K: Insulin-like growth factor receptor I (IGF-IR) and vascular
endothelial growth factor receptor 2 (VEGFR-2) are expressed on the
circulating epithelial tumor cells of breast cancer patients. PLoS
One. 8:e568362013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Grau AM, Wen W, Ramroopsingh DS, Gao YT,
Zi J, Cai Q, Shu XO and Zheng W: Circulating transforming growth
factor-beta-1 and breast cancer prognosis: results from the
Shanghai Breast Cancer Study. Breast Cancer Res Treat. 112:335–341.
2008. View Article : Google Scholar
|
